PET/CT and radiotherapy in gynecological cancer

P. Caroli, S. Fanti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Molecular imaging, in particular, positron emission tomography (PET), has brought an additional dimension to management of patients with cancer and to radiation therapy planning. The combination of PET and computed tomography (CT) in a single system (PET/CT) to form an inherently fused anatomical and functional dataset has provided an imaging modality which could be used as the prime tool in the delineation of tumour volumes and the preparation of patient treatment plans, especially when integrated with virtual simulation. PET imaging (typically using 18F-FDG) can provide data on metabolically active tumour volumes. These functional data have the potential to modify treatment volumes and to guide treatment delivery to cells with particular metabolic characteristics. Depending on its sensitivity and specificity, 18F-FDG PET has been shown to influence the selection of target volumes also in gynecological cancer. The potential of such data from PET was recognized at an early stage and was integrated into the radiotherapy treatment for some gynecological malignancies. In particular 18F-FDG PET has been demonstrated to be useful in patients with cervical cancer candidate to radiotherapy; preliminary data suggest a potential use also in patients with endometrial cancer, uterine sarcoma and ovarian cancer. This paper reviews the state of the art of the integration of PET and PET/CT applications in radiotherapy, and the use of 18F-FDG PET in disease staging, patient selection, treatment planning and treatment evaluation in gynaecological malignancies, in particular in patients with cervical cancer, endometrial cancer, uterine sarcoma and ovarian cancer.

Original languageEnglish
Pages (from-to)533-542
Number of pages10
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume54
Issue number5
Publication statusPublished - Oct 2010

Fingerprint

Positron-Emission Tomography
Radiotherapy
Fluorodeoxyglucose F18
Neoplasms
Uterine Neoplasms
Endometrial Neoplasms
Tumor Burden
Uterine Cervical Neoplasms
Sarcoma
Ovarian Neoplasms
Therapeutics
Molecular Imaging
Positron Emission Tomography Computed Tomography
Patient Selection
Sensitivity and Specificity

Keywords

  • Gynecology
  • Neoplasms
  • Positron-emission tomography
  • Radiotherapy
  • Tomography, X-ray computed

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

PET/CT and radiotherapy in gynecological cancer. / Caroli, P.; Fanti, S.

In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 54, No. 5, 10.2010, p. 533-542.

Research output: Contribution to journalArticle

@article{5f878b7915954dcfbcde3cdd5acc5d7d,
title = "PET/CT and radiotherapy in gynecological cancer",
abstract = "Molecular imaging, in particular, positron emission tomography (PET), has brought an additional dimension to management of patients with cancer and to radiation therapy planning. The combination of PET and computed tomography (CT) in a single system (PET/CT) to form an inherently fused anatomical and functional dataset has provided an imaging modality which could be used as the prime tool in the delineation of tumour volumes and the preparation of patient treatment plans, especially when integrated with virtual simulation. PET imaging (typically using 18F-FDG) can provide data on metabolically active tumour volumes. These functional data have the potential to modify treatment volumes and to guide treatment delivery to cells with particular metabolic characteristics. Depending on its sensitivity and specificity, 18F-FDG PET has been shown to influence the selection of target volumes also in gynecological cancer. The potential of such data from PET was recognized at an early stage and was integrated into the radiotherapy treatment for some gynecological malignancies. In particular 18F-FDG PET has been demonstrated to be useful in patients with cervical cancer candidate to radiotherapy; preliminary data suggest a potential use also in patients with endometrial cancer, uterine sarcoma and ovarian cancer. This paper reviews the state of the art of the integration of PET and PET/CT applications in radiotherapy, and the use of 18F-FDG PET in disease staging, patient selection, treatment planning and treatment evaluation in gynaecological malignancies, in particular in patients with cervical cancer, endometrial cancer, uterine sarcoma and ovarian cancer.",
keywords = "Gynecology, Neoplasms, Positron-emission tomography, Radiotherapy, Tomography, X-ray computed",
author = "P. Caroli and S. Fanti",
year = "2010",
month = "10",
language = "English",
volume = "54",
pages = "533--542",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "5",

}

TY - JOUR

T1 - PET/CT and radiotherapy in gynecological cancer

AU - Caroli, P.

AU - Fanti, S.

PY - 2010/10

Y1 - 2010/10

N2 - Molecular imaging, in particular, positron emission tomography (PET), has brought an additional dimension to management of patients with cancer and to radiation therapy planning. The combination of PET and computed tomography (CT) in a single system (PET/CT) to form an inherently fused anatomical and functional dataset has provided an imaging modality which could be used as the prime tool in the delineation of tumour volumes and the preparation of patient treatment plans, especially when integrated with virtual simulation. PET imaging (typically using 18F-FDG) can provide data on metabolically active tumour volumes. These functional data have the potential to modify treatment volumes and to guide treatment delivery to cells with particular metabolic characteristics. Depending on its sensitivity and specificity, 18F-FDG PET has been shown to influence the selection of target volumes also in gynecological cancer. The potential of such data from PET was recognized at an early stage and was integrated into the radiotherapy treatment for some gynecological malignancies. In particular 18F-FDG PET has been demonstrated to be useful in patients with cervical cancer candidate to radiotherapy; preliminary data suggest a potential use also in patients with endometrial cancer, uterine sarcoma and ovarian cancer. This paper reviews the state of the art of the integration of PET and PET/CT applications in radiotherapy, and the use of 18F-FDG PET in disease staging, patient selection, treatment planning and treatment evaluation in gynaecological malignancies, in particular in patients with cervical cancer, endometrial cancer, uterine sarcoma and ovarian cancer.

AB - Molecular imaging, in particular, positron emission tomography (PET), has brought an additional dimension to management of patients with cancer and to radiation therapy planning. The combination of PET and computed tomography (CT) in a single system (PET/CT) to form an inherently fused anatomical and functional dataset has provided an imaging modality which could be used as the prime tool in the delineation of tumour volumes and the preparation of patient treatment plans, especially when integrated with virtual simulation. PET imaging (typically using 18F-FDG) can provide data on metabolically active tumour volumes. These functional data have the potential to modify treatment volumes and to guide treatment delivery to cells with particular metabolic characteristics. Depending on its sensitivity and specificity, 18F-FDG PET has been shown to influence the selection of target volumes also in gynecological cancer. The potential of such data from PET was recognized at an early stage and was integrated into the radiotherapy treatment for some gynecological malignancies. In particular 18F-FDG PET has been demonstrated to be useful in patients with cervical cancer candidate to radiotherapy; preliminary data suggest a potential use also in patients with endometrial cancer, uterine sarcoma and ovarian cancer. This paper reviews the state of the art of the integration of PET and PET/CT applications in radiotherapy, and the use of 18F-FDG PET in disease staging, patient selection, treatment planning and treatment evaluation in gynaecological malignancies, in particular in patients with cervical cancer, endometrial cancer, uterine sarcoma and ovarian cancer.

KW - Gynecology

KW - Neoplasms

KW - Positron-emission tomography

KW - Radiotherapy

KW - Tomography, X-ray computed

UR - http://www.scopus.com/inward/record.url?scp=79251506695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251506695&partnerID=8YFLogxK

M3 - Article

C2 - 20927020

AN - SCOPUS:79251506695

VL - 54

SP - 533

EP - 542

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 5

ER -